A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 2, 2003, Pages 220-226

  Sarkar, R ^a   Xiaoy, W ^a   Kazazian Jr , H H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AAV 2; Hemophilia A; Murine factor VIII; Single vector

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA;

ADENO ASSOCIATED VIRUS; ANIMAL; BLOOD; C57BL MOUSE; GENE THERAPY; GENE VECTOR; GENETICS; HEMOPHILIA A; MALE; MOUSE; MOUSE MUTANT; NOTE; PHENOTYPE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; DEPENDOVIRUS; DNA, COMPLEMENTARY; FACTOR VIII; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PHENOTYPE;

EID: 0141450407     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00096.x     Document Type: Article

References (43)

1. Antonarakis SE, Kazazian HH. The molecular basis of hemophilia A in man. Trends Genet 1988; 4: 233-7.
2. Kaufman RJ. Expression and structure-function properties of recombinant factor VIII. Transfusion Med Rev 1992; 4: 235-46.
3. Hoyer LW, Wyshock E, Coleman RW. Coagulation factors Vand VIII. In: Haemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd edn. R W Coleman, J Hirch, V J Marder, E W Salzman, eds. Philadelphia: J.B. Lippincott, 1994, 109-33.
4. Rinsch C, Regulier E, Deglon N, Dalle Beuzard Y, Aebischer P. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 1997; 8: 1881-9.
5. Katherine G, Rendahl Leff SE, Otten GR, Spratt SK, Bohl D, Roey MV, Donahue BA, Cohen LK, Mandel RJ, Danoa O, Snyder RO. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat Biot Technol 1998; 16: 757-61.
6. YeX, Rivera VM, Zoltick P, Cerasoli F, Schnell MA, Gao GP, Hughes JV, Gilman M, Wilson JM. regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283: 88-91.
7. Bi 1 lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of hemophilia A. Nat Genet 1995; 10: 119-21.
8. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factorVIII. C deficiency) bleeding. Blood 1982; 60: 727-30.
9. Brinkhous KM, Sandberg H, Garris JB, Mattson C, Palm M, Griggs T, Read MS. Purified human factor VIII procoagulant protein. Comparative hemostatic response after infusions into hemophilic and von Willebrand deiease dogs. Proc Natl Acad Sci USA 1985; 82: 8752.
10. Dwarki VJ, Belloni P, Niijar T, Smith J, Couto L, Rabier M, Clifts S, Berns A, Cohen LK. Gene therapy for hemphilia A. Production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 1995; 92: 1023.
11. Greengard JS, Bodner M, McCormack J, Edwards JL, Sensintaffar D, Hsu DePolo NJ, Mittelstaedt D, De La Vega DJ, Brumm D, Jolly DJ, Chang SMW. Sustained high level factor VIII expression in immunocompetent rabbits and dogs following peripheral intravenous injection of retroviral vector. Thromb Haemost (Suppl.) 1997, 3.
12. VandenDriessche T, Vanslembrouck V, Goovaerts I, Zwinnen H, Vanderhaeghen ML, Collen D, Chuah MKL. Long term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in FVIII deficient mice. Proc Natl Acad Sci USA 1999; 96: 10379-84.
13. Connelly S, Andrews JL, Gallo. AM, Kay DADB, Qian JH, Hoyer L, Kadan MJ, Gorziglia MI, Trapnell BC, McClelland A, Kaleko M. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-81.
14. Gnatenko D, Saenko E, Jesty J, Hearing P, BahouW. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to hemophilia A gene therapy. Br J Haematol 1999; 104: 27-36.
15. Burton M, Nakai H, Colosi P, Cunningham J, Mitchell R, Couto L. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci USA 1999; 96: 12725-30.
16. Hengjum Chao Mao L, Bruce AT, Walsh Sustained CE. expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000; 95: 1594-9.
17. Sarkar R, Gao GP, Chirmule N, Tazelaar. J, Kazazian HH Jr. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther 2000; 11: 881-94.
18. SnyderRO,MiaoCH, PatijnGA, SprattKS,DanosO,NagyD,GownAM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA. Persistent therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-6.
19. Nakai H, Herzog R, Hagstrom J, Walter J, Kung SH, Yang E, Tai SJ, Iwaki Y, Kurtzman GJ, Fisher KJ, Colosi P, Couto LB, High KA. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998; 91: 4600-7.
20. Herzog RW, Yang EY, Couto LB, Hagstrom N, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzmann GJ, high KA. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
21. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thomspon AR, Nichols TC, Read MS, Bellinger DA, Brinkous KM, Kay MA. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64-70.
22. Wang L, Takabe K, Bidlingmaier SM, Charles R III, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96: 3906-10.
23. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154-8.
24. Yonemura H, Sugawara K, Nakashima K, Nakahara Y, Hamamoto T, Mimaki I, Yokomizo K, Tajima Y, Masuda K, Imaizumi A. Efficient production of recombinant human factor VIII by co-expression of the heavy and light chains. Protein Engineering 1993; 6: 669-74.
25. Xiao W, Berta SC, Lu MM, Moscioni D, Tazelaar J,Wilson JM. Adenoassociated virus as a vector for liver-directed gene therapy. J Virol 1998; 72: 10222-6.
26. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adenoassociated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-32.
27. Snyder RO, Xiao X, Samulski RJ. In: Dracopoli N, Hains JL, Korf BR, Moir DT, Morton CC, Seidman CE, Seidman JG, Smith DR., eds. Current Protocols in Human Genetics, 1996; 1:1-24,Wiley, New York.
28. Kung SH, Hagstrom NJ, Cass D, Tai SJ, Lin HF, Stafford DW, High KA. et al. Human FIX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998; 91: 784-90.
29. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic analysis PCR. Real-time monitoring of DNA amplification reaction. Biotechnology 1993; 11: 1026-30.
30. Livak K, Flood S, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Applications 1995; 4: 357-62.
31. Pittman D.D, Alderman E.A, Tomkinson K.N, Wang J.H, Giles A.R, kaufman R.J. Biochemical, immunological, and in-vivo functional characterization of B-domain deleted factor VIII. Blood 1993; 81: 2925-35.
32. Yan Z, Zhang Y, Duan D, Engelhardt J.F. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000; 97: 6716-21.
33. Editorial. Gene therapy and the germline. Nat Med 1999; 5: 245.
34. Guo ZS, Wang L.H, Eisensmith R.C, Woo S.L.C. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirusmediated gene transfer. Gene Ther 1996; 3: 802-10.
35. Duan D, Yan Z, Yue Y, Ding W, Engelhardt J.F. Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differntiation. J Virol 2001; 75: 7662-71.
36. Chao H, Liu Y, Rabinowitz J, Li C, Samulski R.J, Walsh C.E. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619-23.
37. Xiao W, Chirmule N, berta SC, Mccullough B, Gao G, Wilson J.M. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994-4003.
38. Kaufman R.J, Wasley L.C, Dorner A.J. Synthesis, processing and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-62.
39. Hall SJ, Bar-Chama N, Ta, S Gordon JW. Direct exposure of mouse spermatogenic cells to high doses of adenovirus gene therapy vector does not result in germ cell transduction. Hum Gene Ther 2000; 11: 1705-12.
40. Arruda V.R, Fields P.A, Milner R,Wainwright L, Miguel M.P.D, Donovan P.J, Herzog R.W, Nichols T.C, Biegel J.A, Razavi M, Dake M, Huff D, Flake A.W, Couto L, Kay M.A, High K.A. Lack of germline transmission of vector sequences following systematic administration of recombinant AAV02 vector in males. Mol Ther 2001; 4: 586-92.
41. Ye X, Gao G.P, Pabin C, Raper S.E, Wilson J.M. Evaluating the potential of germline transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gene Ther 1998; 9: 2135-42.
42. Peters A.H, Drumm J, Ferrell C, Roth D.A, Roth D.M, Mccaman M, Novak P.L, Friedman J, Engler R, Braun R.E. Absence of germline infection in male mice following intraventricular injection of adenovirus. Mol Ther 2001; 4: 603-13.
43. Kazazian Jr. H.H Endogenous insertional mutations in the human germline. Nat Genet 1999; 22: 130.